Literature DB >> 25614318

Immune cell promotion of metastasis.

Takanori Kitamura1, Bin-Zhi Qian1, Jeffrey W Pollard2.   

Abstract

Metastatic disease is the major cause of death from cancer, and immunotherapy and chemotherapy have had limited success in reversing its progression. Data from mouse models suggest that the recruitment of immunosuppressive cells to tumours protects metastatic cancer cells from surveillance by killer cells, which nullifies the effects of immunotherapy and thus establishes metastasis. Furthermore, in most cases, tumour-infiltrating immune cells differentiate into cells that promote each step of the metastatic cascade and thus are novel targets for therapy. In this Review, we describe how tumour-infiltrating immune cells contribute to the metastatic cascade and we discuss potential therapeutic strategies to target these cells.

Entities:  

Mesh:

Year:  2015        PMID: 25614318      PMCID: PMC4470277          DOI: 10.1038/nri3789

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  124 in total

1.  Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells.

Authors:  Purevdorj B Olkhanud; Dolgor Baatar; Monica Bodogai; Fran Hakim; Ronald Gress; Robin L Anderson; Jie Deng; Mai Xu; Susanne Briest; Arya Biragyn
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

Review 2.  Interferons, immunity and cancer immunoediting.

Authors:  Gavin P Dunn; Catherine M Koebel; Robert D Schreiber
Journal:  Nat Rev Immunol       Date:  2006-11       Impact factor: 53.106

3.  Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling.

Authors:  Wei Tan; Weizhou Zhang; Amy Strasner; Sergei Grivennikov; Jin Q Cheng; Robert M Hoffman; Michael Karin
Journal:  Nature       Date:  2011-02-16       Impact factor: 49.962

4.  Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice.

Authors:  Ana M Gil-Bernabé; Spela Ferjancic; Monika Tlalka; Lei Zhao; Philip D Allen; Jae Hong Im; Karla Watson; Sally A Hill; Ali Amirkhosravi; John L Francis; Jeffrey W Pollard; Wolfram Ruf; Ruth J Muschel
Journal:  Blood       Date:  2012-02-10       Impact factor: 22.113

Review 5.  Neutralizing tumor-promoting chronic inflammation: a magic bullet?

Authors:  Lisa M Coussens; Laurence Zitvogel; A Karolina Palucka
Journal:  Science       Date:  2013-01-18       Impact factor: 47.728

Review 6.  Microenvironmental regulation of metastasis.

Authors:  Johanna A Joyce; Jeffrey W Pollard
Journal:  Nat Rev Cancer       Date:  2008-03-12       Impact factor: 60.716

Review 7.  Tumour-associated macrophages and cancer.

Authors:  Jenny Cook; Thorsten Hagemann
Journal:  Curr Opin Pharmacol       Date:  2013-06-15       Impact factor: 5.547

Review 8.  The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis.

Authors:  Sandra S McAllister; Robert A Weinberg
Journal:  Nat Cell Biol       Date:  2014-08       Impact factor: 28.824

9.  Wiskott-Aldrich syndrome protein regulates leukocyte-dependent breast cancer metastasis.

Authors:  Dan Ishihara; Athanassios Dovas; Lorena Hernandez; Maria Pozzuto; Jeffrey Wyckoff; Jeffrey E Segall; John S Condeelis; Anne R Bresnick; Dianne Cox
Journal:  Cell Rep       Date:  2013-08-01       Impact factor: 9.423

10.  Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature.

Authors:  Qiong-wen Zhang; Lei Liu; Chang-yang Gong; Hua-shan Shi; Yun-hui Zeng; Xiao-ze Wang; Yu-wei Zhao; Yu-quan Wei
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

View more
  439 in total

Review 1.  Immunological Consequences of Epithelial-Mesenchymal Transition in Tumor Progression.

Authors:  Peter J Chockley; Venkateshwar G Keshamouni
Journal:  J Immunol       Date:  2016-08-01       Impact factor: 5.422

Review 2.  How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy.

Authors:  Jinyang Li; Ben Z Stanger
Journal:  Cancer Res       Date:  2020-06-18       Impact factor: 12.701

Review 3.  Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment.

Authors:  Yunlu Dai; Can Xu; Xiaolian Sun; Xiaoyuan Chen
Journal:  Chem Soc Rev       Date:  2017-05-18       Impact factor: 54.564

4.  Colon cancer stem cells: Potential target for the treatment of colorectal cancer.

Authors:  Riya Gupta; Lokesh Kumar Bhatt; Thomas P Johnston; Kedar S Prabhavalkar
Journal:  Cancer Biol Ther       Date:  2019-05-03       Impact factor: 4.742

Review 5.  Genomic Instability in Cancer: Teetering on the Limit of Tolerance.

Authors:  Noemi Andor; Carlo C Maley; Hanlee P Ji
Journal:  Cancer Res       Date:  2017-04-21       Impact factor: 12.701

6.  Peritoneal carcinomatosis of colorectal cancer is characterized by structural and functional reorganization of the tumor microenvironment inducing senescence and proliferation arrest in cancer cells.

Authors:  Caroline Theresa Seebauer; Stefan Brunner; Gabriel Glockzin; Pompiliu Piso; Petra Ruemmele; Hans-Juergen Schlitt; Edward Kenneth Geissler; Stefan Fichtner-Feigl; Rebecca Kesselring
Journal:  Oncoimmunology       Date:  2016-10-14       Impact factor: 8.110

7.  The effects of monocytes on tumor cell extravasation in a 3D vascularized microfluidic model.

Authors:  A Boussommier-Calleja; Y Atiyas; K Haase; M Headley; C Lewis; R D Kamm
Journal:  Biomaterials       Date:  2018-03-05       Impact factor: 12.479

Review 8.  The pan-therapeutic resistance of disseminated tumor cells: Role of phenotypic plasticity and the metastatic microenvironment.

Authors:  Bo Ma; Alan Wells; Amanda M Clark
Journal:  Semin Cancer Biol       Date:  2019-07-31       Impact factor: 15.707

9.  Lymphatic vessels regulate immune microenvironments in human and murine melanoma.

Authors:  Amanda W Lund; Marek Wagner; Manuel Fankhauser; Eli S Steinskog; Maria A Broggi; Stefani Spranger; Thomas F Gajewski; Kari Alitalo; Hans P Eikesdal; Helge Wiig; Melody A Swartz
Journal:  J Clin Invest       Date:  2016-08-15       Impact factor: 14.808

10.  Dynamic interplay between tumour, stroma and immune system can drive or prevent tumour progression.

Authors:  R J Seager; Cynthia Hajal; Fabian Spill; Roger D Kamm; Muhammad H Zaman
Journal:  Converg Sci Phys Oncol       Date:  2017-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.